GLAXO WELLCOME EPIVIR/RETROVIR FIXED-DOSE COMBO TABLET FILING "IMMINENT" FOR HIV, COMPANY SAYS; ABACAVIR NUCLEOSIDE ANALOGUE NDA PLANNED FOR 1998
Glaxo Wellcome is preparing to file an NDA for a twice-daily fixed-dose combination of its two nucleoside analogue anti-HIV treatments, Retrovir (zidovudine) and Epivir (lamivudine).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth